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The aim of this study was to compare various formulations solid dispersion pellets (SDP), nanostructured lipid carriers
(NLCs) and a self-microemulsifying drug delivery system (SMEDDS) generally accepted to be the most efficient
drug delivery systems for BCS II drugs using fenofibrate (FNB) as a model drug. The size and morphology of NLCs
and SMEDDS was characterized by dynamic light scattering (DLS) and transmission electron microscopy (TEM).
Their release behaviors were investigated in medium with or without pancreatic lipase. The oral bioavailability of
the various formulations was compared in beagle dogs using commercial Lipanthyl® capsules (micronized formulation) as
a reference. The release of FNB from SDP was much faster than that from NLCs and SMEDDS in medium without lipase,
whereas the release rate from NLCs and SMEDDS was increased after adding pancreatic lipase into the release medium.
However, NLCs and SMEDDS increased the bioavailability of FNB to 705.11% and 809.10%, respectively, in comparison
with Lipanthyl® capsules, although the relative bioavailability of FNB was only 366.05% after administration of SDPs. Thus,
lipid-based drug delivery systems (such as NLCs and SMEDDS) may have more advantages than immediate release
systems (such as SDPs and Lipanthyl® capsules).
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BioavailabilityBackground
According to the definition of the Biopharmaceutics Clas-
sification System (BCS) proposed by Amidon in 1995,
both BCS II and IV drugs are poorly soluble in aqueous
solution [1]. About 40% of new drug candidates identified
by chemical screening are poorly soluble in water (BCS II
or IV drugs), which greatly hinders their translation into
the clinic [2]. However, the transmembrane permeation
behavior of BCS II drugs is significantly different to that of
BCS IV drugs. Generally, the apparent permeability coeffi-
cient (Papp) of BCS II drugs is greater than 10-6, whereas
the Papp of BCS IV drugs is lower than 10-8 owing to vari-
ous barriers such as low dissolution rate, low transmem-
brane permeability, efflux by transporter in the gut wall* Correspondence: qijianping@fudan.edu.cn
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unless otherwise stated.and first pass effect by metabolic enzymes [3]. To improve
the oral bioavailability of these drugs, novel formulation
technologies or drug delivery systems have emerged, in-
cluding solid dispersion [4,5], nanocrystals [6], cyclodex-
trin inclusion [7,8], nanoemulsions [9], polymeric and
lipidic nanoparticles (e.g. PLGA nanoparticles, solid lipid
nanoparticles and nanostructure lipid carriers) [10-12].
These formulations can enhance oral absorption of
drug molecules by improving dissolution in the gastro-
intenstinal tract (GIT) [6], facilitating adhesive interac-
tions within the mucosa [13], increasing drug stability
and improving lymphatic transport [14]. Nevertheless,
different formulations have distinguishing features and
facilitate absorption by distinct mechanisms. Solid dis-
persion and cyclodextrin inclusion improve the dissol-
ution rate of poorly soluble drugs, but do not increasetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The particle sizes and polydispersity index of FNB-loaded
SMEDDS in different dispersion media (n = 3).
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fast-release system that has similar effects to those of
solid dispersion and cyclodextrin inclusion [6], whereas
nanoparticles can alter the permeability of the intestinal
membrane by uptake of intact nanoparticles, facilitating
adhesion and retention in the GIT and improving mem-
brane fluidity, thus leading to increased absorption via
the paracellular or transcellular route [17,18]. Further-
more, the fate of nanoparticles containing lipids in the
GIT is different to to that of polymer nanoparticles. Diges-
tion products of lipid nanoparticles can solubilize lipo-
philic drugs and the presence of endogenous bile salts
may alter the intrinsic permeability of the intestinal mem-
brane [19,20]. Although each drug delivery system may be
recognized to improve oral bioavailability of poorly soluble
drugs, we aimed to identify the optimal formulation tech-
nology for delivery of BCS II or IV drugs. Therefore, in
this study, we first compared the bioavailability of different
drug delivery systems loaded with the BCS II drug, fenofi-
brate (FNB).
FNB, a widely used hypolipidemic agent, is a typical
BCS II drug. Due to its very low solubility in aqueous so-
lution, the oral bioavailability is limited by slow dissolution
[21]. In the clinic, micronized FNB (Lipanthyl® capsules)
showed significantly improved dissolution and enhanced
oral bioavailability. More recently, various oral carrier sys-
tems were developed to increase oral absorption of FNB,
including solid dispersion [4], a self-microemulsifying
drug delivery system [22], liposome containing bile salts
[23], mesoporous carbon [24], nanocystals [21] and lipid-
based formulations [25]. Although these systems success-
fully increase the oral bioavailability of FNB, the optimal
formulation remains to be identified by comparing the
oral bioavailability of FNB after administration of different
formulations.
Herein, the oral bioavailability of FNB-loaded into the
lipid-based delivery systems, SMEDDS and NLCs, was
compared with that of fast-release FNB SDPs and mi-
cronized Lipanthyl® capsules in beagle dogs.Results and discussion
Preparation and characterization of SDP, NLCs and
SMEDDS
FNB-loaded SDP, NLCs and SMEDDS were prepared suc-
cessfully. Since FNB-loaded SDPs and NLCs were prepared
according to our previous study [25,26], the detailed
characterization data are not shown in this report. The par-
ticle size of the obtained NLCs was 93.76 ± 1.25 nm (poly-
dispersity index (PDI), 0.222 ± 0.014), the zeta potential was
-29.1 ± 4.1 mV and the entrapment efficiency was approxi-
mately 96.66 ± 1.01%, which are similar to the values ob-
tained in our previous study [25]. FNB-loaded SMEDDS
were microemulsified in deionized water, pH 1.2 HClsolution and pH 6.8 PBS immediately; the particle size and
PDI are shown in Figure 1.Morphology
Transmission electron microscopy (TEM) was employed
to observe the morphology of NLCs and microemulsions
formed by SMEDDS; micrographs are presented in Figure 2.
The NLCs (Figure 2A) were spherical in shape and approxi-
mately 100 nm in size. TEM showed that the SMEDDS
were emulsified in deionized water to generate uniform
spherical microemulsion droplets approximately 20 nm in
size (Figure 2B).In vitro release
The profiles of FNB release from the three test formula-
tions and the reference (commercial Lipanthyl® capsules
containing micronized FNB) in the media with or without
pancreatic lipase are shown in Figure 3. FNB was released
rapidly from Lipanthyl® capsules and SDPs, with a cumula-
tive release of more than 80% within 60 min. Only about
25% of the FNB was released from SMEDDS within 24 h
and even less (about 12%) from the NLCs. However,
pancreatic lipase changed the dissolution behavior of
SMEDDS and NLCs. In release medium containing
pancreatic lipase, the release of FNB from SDPs and
Lipanthyl® capsules was not altered significantly com-
pared with that in medium without lipase. Nevertheless,
the release from SMEDDS and NLCs was evidently im-
proved, with more than 60% and 40% of FNB released
from SMEDDS and NLCs in 24 h, respectively. The
similarity factor (f2), which is recommended by FDA for
evaluation of the similarity of release profiles [27], was
Figure 2 Morphology of FNB-loaded NLCs (A) and microemulsions droplets formed by SMEDDS (B) observed by transmission
electron microscopy.
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lease according to the following formula:












where xti and xri are the cumulative release of time interval
“i” in release medium with and without pancreatic lipase,Figure 3 In vitro release profiles of FNB from SDP, NLCs, SMEDDS and
(B) pancreatic lipase (n = 3).respectively, and n is the time interval. When f2 is between
50 and 100, the variation in every observation point be-
tween the two release profiles is not more than 10%, which
is considered to represent similarity. If f2 < 50, the two re-
lease profiles are considered to be dissimilar. The f2 of the
four formulations are displayed in Table 1. The release pro-
files of FNB from Lipanthyl® capsules and SDPs were not
altered by the addition of lipase to the release medium,
although the release profiles from SMEDDS and NLCs in
two release media differed considerably, which indicates
that intestinal lipase is important to the release of poorlyLipanthyl® capsules in release media without (A) or with
Table 1 The f2 values of release profiles of FNB in release
media with or without pancreatic lipase
Formulations Lipanthyl® capsules SDP SMEDDS NLCs
f2 67.1 60.7 36.5 42.4
Weng et al. Journal of Nanobiotechnology 2014, 12:39 Page 4 of 8
http://www.jnanobiotechnology.com/content/12/1/39soluble drugs from lipid-based drug delivery systems, such
as SMEDDS and NLCs.Oral bioavailability
To illustrate the optimal formulation for BCS II drugs, oral
bioavailability of FNB-loaded SDPs, NLCs and SMEDDS
in beagle dogs were compared. The mean plasma FNB
concentration versus time plots of the four formulations
are shown in Figure 4 and the pharmacokinetic parameters
obtained by analysis based on statistical moment theory
are shown in Table 2.
After oral gavage administration of the three FNB formu-
lations to beagle dogs, the Cmax and AUC of all of the
formulations were improved compared with those of
Lipanthyl® capsules. NLCs and SMEDDS in particular
exhibited enhanced absorption compared with SDPs.
The relative bioavailability of NLCs and SMEDDS were
705.11% and 809.10%, respectively, compared with Lipan-
thyl® capsules, while that of SDPs was only 366.05%. Com-
pared with Lipanthyl® capsules, the Tmax, MRT and t1/2 of
fenofibric acid showed no significant changes after oral
administration of all three formulations.
Theoretically, the oral bioavailability of BCS II drugs is
restricted mainly by poor dissolution in the GIT. Gener-
ally speaking, the oral bioavailability of BCS II drugs is
improved greatly if the in vitro dissolution is enhanced
[28]. Therefore, micronization, nanosuspension, solid
dispersion and cyclodextrin inclusion are widely used toFigure 4 Mean plasma concentration-time profiles of fenofibric
acid in beagle dogs after oral administration of FNB-loaded
SDP, NLCs, SMEDDS and Lipanthyl® capsules (n = 6).improve the oral bioavailability of BCS II drugs [28].
Previous in vitro and in vivo evaluations of the reference,
Lipanthyl® capsules, which are a product of micronized
FNB and nanosuspensions of FNB suggested the FNB is
rapidly released from Lipanthyl® capsules, SDPs and
nanosuspensions, and that SDPs or nanosuspensions im-
prove the oral bioavailability of FNB compared with that
of the Lipanthyl® capsules [29]. Similar dissolution does
not lead to the same oral absorption, which may be due
to the various influences of the GIT contents on dissol-
ution of drugs from the different formulations.
Although FNB was released very slowly and in small
amounts from lipid-based drug delivery systems, such
as NLCs and SMEDDS, the cumulative release of FNB
increased with introduction of lipase. Pancreatic lipase,
bile salts and phospholipids are continuously secreted
into the GIT. Lipid-based drug delivery systems are
digested by pancreatic lipase to form secondary struc-
tures, such as mixed micelles, cubic or hexagonal nano-
particles and vesicular carriers [30]. Therefore, drugs can
be solubilized in these secondary derivatives when lipid-
based formulations are digested [31]. SDPs, nanosuspen-
sions or micronized drugs significantly increase drug
dissolution, but oral absorption is promoted only by the
original absorption pathways of the drug itself. Never-
theless, lipid-based drug delivery systems may enhance
the absorption of drugs through diverse pathways [32].
On the one hand, NLCs and SMEDDS can adhere to the
gut wall to increase retention time in GIT. The particle
sizes of NLCs and SMEDDS were below 100 nm, which
endows them with a massive specific surface area and facil-
itates the adhesion of nanoparticles by the mucus layer
[33,34]. On the other hand, many reports have suggested
that the digestion of lipid-based drug delivery systems in
the GIT is the most important factor required to enhance
the absorption of poorly soluble drugs [35-37]. Exogenous
lipids stimulate the secretion of biliary lipids (bile salts,
phospholipids and cholesterol), which combine with lipid
digestion products to generate a series of colloidal species,
including micelles, mixed micelles, vesicles and emulsion
droplets [38]. These colloidal species provide a reservoir of
solubilized drug at the absorptive site and generate the con-
centration gradient required to drive improved absorption.
Luminal amphiphiles, such as bile salts, may also enhance
the solubilization of drugs by improving wetting at concen-
trations below the critical micellar concentration [39].
Thus, the drug concentration increases during the diges-
tion process, which improves the transport across non-
stirred water layers and then the bio-membranes. In
addition, fatty acids and monoglycerides produced during
digestion increase the fluidity and permeability of mem-
branes due to their surface activity, which is also an import-
ant factor in enhancing drug absorption [40]. Furthermore,
lymphatic transport can also increase the oral bioavailability
Table 2 The main pharmacokinetic parameters of fenofibric acid in beagle dogs after oral administration of
FNB-loaded SDP, NLCs, SMEDDS and Lipanthyl® capsules (n = 6)
Parameters Lipanthyl® capsules SDP NLCs SMEDDS
Cmax (μg/mL) 0.41 ± 0.17 1.82 ± 1.18* 3.87 ± 1.40*
# 5.31 ± 1.18*#▲
Tmax (h) 1.04 ± 0.29 1.13 ± 0.59 0.92 ± 0.34 0.96 ± 0.43
t1/2 (h) 3.40 ± 1.55 9.58 ± 7.64 8.09 ± 3.25* 6.25 ± 2.15*
MRT(0-t)(h) 4.24 ± 0.24 4.45 ± 0.18 4.22 ± 0.42 4.00 ± 0.28
AUC(0-t) (μg/mL*h) 2.13 ± 0.69 7.81 ± 4.36* 15.04 ± 2.34*# 17.26 ± 3.43*#
F1 (%) — 366.05 705.11 809.10
F2 (%) — — 192.62 221.03
F3 (%) — — — 114.75
F1, F2 and F3 are relative bioavailability of other formulations compared with Lipanthyl® capsules, SDP and NLCs, respectively.
*P < 0.05, compared with Lipanthyl® capsule.
#P < 0.05, compared with SDP.
▲P < 0.05, compared with NLCs.
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atic transport of lipophilic compounds by simulating the
production of chylomicrons. Lipophilic drugs enter the
lymphatic system in association with the triglyceride core
of the chylomicrons [42]. The digestibility of the vehicle is a
prerequisite for the production of the fatty acids necessary
to drive chylomicron production [43].
Conclusion
FNB-loaded SDPs, NLCs and SMEDDS were prepared and
their in vitro and in vivo properties were compared. SDPs
significantly increased the release of FNB in medium with
and without lipase, which is similar to the characteristics of
Lipanthyl® capsules. Pancreatic lipase improved the release
of FNB from NLCs and SMEDDS remarkably. However,
the oral bioavailability of FNB after administration of NLCs
and SMEDDS was significantly higher than that of SDP
and Lipanthyl® capsules (P < 0.05). Therefore, lipid-based
drug delivery systems (such as NLCs and SMEDDS) are
more advantageous than the other drug delivery systems
(solid dispersion or micronization) for BCS II drugs, due to
the multiple absorption enhancement mechanisms. Lipid-
based drug delivery systems may be an excellent candidate
for oral formulation of insoluble drugs.
Methods
Materials
FNB was purchased from Nhwa Pharmaceutical Group
(Xuzhou, China). Polyvinylpyrrolidone (PVP K30) was
kindly gifted from China Division, ISP Chemicals Co.
(Shanghai, China). Non-pareil pellets (Suglets® sugar
spheres PF101, 710–850 μm in diameter) were provided
by NP Pharm (Bazainville, France). Precirol ATO 5 and
Captex 100 were kindly provided by Gattefossé Co. (Saint
Priest, Cedex, France) and Abitec Co. (OH, USA), respect-
ively. Polysorbate 80 (Tween-80) was supplied by Shenyu
Pharmaceutical and Chemical Co., Ltd (Shanghai). Oleoylmacrogolglycerides (Labrafil M® 1944 CS) and diethylene
glycol monoethyl ether (Transcutol P®) were purchased
from Gattefossé Co. Ethoxylated castor oil (Cremophor®
EL) was obtained from BASF Corporation (Ludwigshafen,
Germany). HPLC grade methanol and acetonitrile were
purchased from Tedia (Carson City, NV, USA). Deionized
water was prepared using a Milli-Q purification system
(Millipore, Billerica, MA, USA). All other chemicals were of
analytical grade and were used as received.
Preparation of FNB-loaded delivery systems
Preparation of solid dispersion pellets (SDP)
FNB-loaded SDPs were prepared using a Mini-Glatt fluid-
bed coater (Wurster insert; Glatt GmbH, Binzen, Germany)
based on previously established procedures [26]. FNB, PVP
K30 and sodium dodecyl sulfate (SDS) (4:3:3, w/w) were
dissolved in 90% ethanol. The resulting solution was
sprayed through a nozzle (0.5 mm in diameter) onto the
fluidized non-pareil pellets to obtain a coating weight gain
of approximately 100%. The detailed operating conditions
were as follows: product temperature, 35°C − 40°C; air flow
rate, 97–103 m3/h; spray rate, 0.6 mL/minute; atomizing air
pressure, 1.4–1.5 bar. The pellets were further dried for
15 min after coating completion.
Preparation of nanostructured lipid carriers (NLCs)
The NLC suspension was prepared by the melting-
emulsification method according to our previously de-
scribed procedures [25]. Briefly, 1.14 g solid lipid phase
(Precirol ATO 5) and 0.48 g liquid lipid phase (Captex
100) were melted at 80°C and mixed. Then 60 mg FNB
was dissolved in the lipid mixture. The melted mixture
was then dispersed in a hot (80°C) aqueous solution
(30 mL) containing Tween-80 (2%, w/v) for 3 min at a rate
of 8,000 rpm using a high-speed Ultra Turrax blender
(QilinBeier, Jiangsu, China) to produce the coarse emulsion.
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a high-pressure homogenizer (Microfluids, Nano DeBee,
USA) for three cycles under 20,000 psi. The obtained
hot NLC suspension was cooled to room temperature
for use in further investigations.Preparation of self-microemulsifying drug delivery
systems (SMEDDS)
The formulation of FNB-loaded SMEDDS was performed
according to previously described methods with modifica-
tions [44]. Briefly, FNB, Labrafil M 1944 CS (oil phase),
Cremophore EL (surfactant) and Transcutol P (co-surfac-
tant) were mixed in ratio of 40/520/585/195 (w/w). The
obtained SMEDDS was stored at 4°C before use.Measurement of particle size
Particle size was measured by Zetasizer Nano® (Malvern
Instruments, Malvern, UK) equipped with a 4 mW He-Ne
laser (633 nm) at 25°C. The NLC suspension was diluted
15-fold with deionized water before measurement. The
particle size of SMEDDS was determined after microe-
mulsification in deionized water. Three measurements
were conducted, and the number of runs in each measure-
ment was automatically determined by the software.Transmission electron microscopy (TEM)
TEM was used to characterize the morphology of NLCs
and SMEDDS. Prior to examination, microemulsion drops
were obtained by emulsifying SMEDDS in deionized
water. The NLCs suspension and microemulsion droplets
were then placed on copper grids and negatively stained
with 2% (w/v) phosphotungstic acid for 5 min at room
temperature. Finally, the grids bearing NLCs and microe-
mulsion droplets were observed with a JEM-1230 trans-
mission electron microscope (JEOL, Tokyo, Japan).Entrapment efficiency of NLCs
The entrapment efficiency of NLCs was determined by
ultrafiltration. Briefly, 0.4 mL NLCs was added to an
ultrafiltration tube (100 kD) and then centrifuged for
10 min at 4,000 × g. The concentrations of FNB in the
filtrate (Cfree) was determined by HPLC directly. The
concentration of FNB original NLCs (Ctotal) were deter-
mined as following method. Briefly, 0.4 mL of NLCs
suspension was dissolved in 100 mL methanol. The FNB
released into methanol from NLCs rapidly with the help
of ultrasound. After ultrasound treatment of 20 min,
the mixed solution was centrifuged for 10 min under
10,000 × g. The supernatant was injected into HPLC to
determine Ctotal. The entrapment efficiency (EE) was




The release test was performed in a ZRS-8G dissolution
tester (Tianda Tianfa Technology Co. Ltd, Tianjin,
China) according to the Chinese Pharmacopoeia (2010)
Appendix Method III. To clarify the effect of lipase on
the release of lipid formulations (NLCs or SMEDDS), we
selected two different release media; phosphate balanced
saline (pH 6.8) containing 2% Cremophor EL with or
without pancreatic lipase (100 IU/mL). Four formula-
tions (containing 3 mg FNB) were added into 100 mL
release medium that was thermostatically maintained at
37 ± 0.5°C and stirred at a revolution speed of 100 rpm.
SDP was sealed into hard gelatin capsules. Samples of
0.5 mL were withdrawn at specific time intervals and
immediately ultrafiltered (Millipore, 100 kD) at 4,000 × g
for 10 min. The ultrafiltrate was assayed for FNB by
HPLC as described later in the text.
Bioavailability study
The bioavailability of SDPs, NLCs and SMEDDS con-
taining FNB was evaluated in beagle dogs using com-
mercially available Lipanthyl® capsules (micronized FNB,
Solvay Pharma) as a reference. Beagle dogs (adult males,
15.0 ± 0.5 kg) used in the experiments received care in
compliance with the Principles of Laboratory Animal
Care and the Guide for the Care and Use of Laboratory
Animals. Experiments followed protocols approved by
the Fudan University Institutional Animal Care and Use
Committee.
Four formulations were administered to the dogs by
oral gavage at an equivalent dose of 3 mg/kg FNB. Blood
samples (1.5 mL) were then collected into heparinized
tubes at designated time intervals: 0.25, 0.5, 0.75, 1, 1.25,
1.5, 2, 4, 6, 8, 10 and 12 h. Plasma was separated by cen-
trifugation for 10 min at 4,000 × g and frozen at -18°C
for subsequent analysis. FNB, as a prodrug, is rapidly
metabolized into its major active metabolite, fenofibric
acid (FA), after absorption. Intact FNB cannot be de-
tected in the plasma after oral administration; therefore,
pharmacokinetic evaluation of FNB was based on the
quantification of FA in the plasma [45]. FA in dog
plasma was extracted by liquid-liquid extraction proce-
dures established in our previous study and the concen-
tration of FA was determined by HPLC [23].
Pharmacokinetic parameters were calculated by non-
compartmental analysis based on statistical moment the-
ory using DAS professional software version 2.0 (Anhui,
China). The pharmacokinetic parameters, such as peak
plasma concentration (Cmax), the time to maximum
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concentration-time curve between 0 and 12 h (AUC0-12)
were determined.
HPLC analysis
Both in vitro and in vivo samples were determined by
HPLC system (Agilent 1260 series, California, USA) com-
prising an auto sampler, a pump, a column oven, and a
tunable ultraviolet detector. The analytical column was a
C18 column (Diamonsil®, 5 μm, 4.6 mm × 250 mm,
Dikma, China) guarded with a refillable precolumn
(C18, 2.0 mm × 20 mm, Alltech, USA). The flow rate
was 1.0 mL/min. The UV-detector was set at a wave-
length of 287 nm. The column temperature was set to
40°C. In terms of in vitro determination of FNB, the
mobile phase consisted of methanol and deionized
water mixed at a ratio of 90/10 (v/v). However, the mo-
bile phase was composed of a mixture of methanol,
water and 10% phosphoric acid (70/30/1, v/v/v) for
in vivo determination of FA. Indomethacin (10 μg/mL)
was used as an internal standard [23].
Statistical analysis
All data were expressed as mean ± standard deviation
(SD). One-way ANOVA followed by Tukey’s test was
performed to assess the statistical significance of differ-
ences. Results with P < 0.05 were considered statistically
significant.
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